EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Exploring the SAR of 1,2,3‐Triazoles as Tumor‐Associated Carbonic Anhydrases IX and XII Inhibitors for Anticancer Applications

Naveen Chauhan, Neelam Yadav, Prince Kumar, Suresh Kumar iD, Ranjana Aggarwal

Archiv der Pharmazie · 2025-07 · 358 (7)

DOI: 10.1002/ardp.70041 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Archiv der Pharmazie, online erschienen am 09.07.2025. Verfasst von Naveen Chauhan und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Chemistry, Kurukshetra University, Kurukshetra, Haryana, India. Hauptthemen laut MEDLINE: Carbonic Anhydrase Inhibitors, Antineoplastic Agents, Triazoles, Carbonic Anhydrase IX. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 116 Literaturangaben. Gefördert von: The authors received no specific funding for this work..

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The search for novel anticancer agents has brought carbonic anhydrase (CA) isoforms IX and XII into focus due to their critical role in tumor growth and survival, particularly under hypoxic conditions. These tumor‐associated enzymes regulate pH and ion transport in cancer cells, making them attractive therapeutic targets. Among the compounds explored as CA inhibitors, 1,2,3‐triazoles stand out for their versatile CA inhibition potential and favorable pharmacokinetic properties. 1,2,3‐triazole scaffold, easily synthesized via click reactions, offers a promising framework for developing selective inhibitors against CA IX and XII. Recent research highlights the anticancer potential of 1,2,3‐triazole derivatives, which selectively inhibit these isoforms, impairing tumor microenvironment regulation and thus enhancing cancer treatment efficacy. The present review explores the structure–activity relationships (SAR) of 1,2,3‐triazole scaffolds as tumor‐associated CA IX and XII inhibitors. We provide insights into their design and therapeutic potential by examining key structural modifications that enhance potency and selectivity. This comprehensive analysis aims to guide the future development of 1,2,3‐triazole‐based CA inhibitors for use as antitumor agents.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carbonic Anhydrase InhibitorsAntineoplastic AgentsTriazolesCarbonic Anhydrase IXCarbonic AnhydrasesNeoplasmsHumansStructure-Activity RelationshipAnimalsAntigens, NeoplasmMolecular Structure

Stichwörter der Autor:innen

1,2,3‐triazoleCA IX and CA XIIanticancercarbonic anhydrasestructure‐activity relationship

Substanzen

Carbonic Anhydrase InhibitorsAntineoplastic AgentsTriazolesCarbonic Anhydrase IXCarbonic Anhydrasescarbonic anhydrase XIIAntigens, NeoplasmCA9 protein, human

Autor:innen und Institutionen

  • Department of Chemistry, Kurukshetra University, Kurukshetra, Haryana, India.
  • Council of Scientific and Industrial Research-National Institute of Science Communication and Policy Research, New Delhi, India.

ORCID-Profile: Suresh Kumar

Förderung

  • The authors received no specific funding for this work.

Zitieren

APA

Chauhan, N., Yadav, N., Kumar, P., Kumar, S., & Aggarwal, R. (2025). Exploring the SAR of 1,2,3‐Triazoles as Tumor‐Associated Carbonic Anhydrases IX and XII Inhibitors for Anticancer Applications. Archiv der Pharmazie, 358(7). https://doi.org/10.1002/ardp.70041

Vancouver

Chauhan N, Yadav N, Kumar P, Kumar S, Aggarwal R. Exploring the SAR of 1,2,3‐Triazoles as Tumor‐Associated Carbonic Anhydrases IX and XII Inhibitors for Anticancer Applications. Archiv der Pharmazie. 2025;358(7). doi:10.1002/ardp.70041

BibTeX
@article{Chauhan2025,
  author = {Chauhan, Naveen and Yadav, Neelam and Kumar, Prince and Kumar, Suresh and Aggarwal, Ranjana},
  title = {Exploring the SAR of 1,2,3‐Triazoles as Tumor‐Associated Carbonic Anhydrases IX and XII Inhibitors for Anticancer Applications},
  journal = {Archiv der Pharmazie},
  year = {2025},
  volume = {358},
  number = {7},
  doi = {10.1002/ardp.70041}
}
Kostenlos starten →